A new era in phosphate binder therapy: What are the options?

Kidney International

Volumn 70, Issue SUPPL. 105, 2006, Pages

  Salusky, I B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chronic kidney disease; Hyperphosphatemia; Phosphate binders

Indexed keywords

ALUMINUM CARBONATE; ALUMINUM DERIVATIVE; ALUMINUM HYDROXIDE; CALCITRIOL; CALCIUM ACETATE; CALCIUM CARBONATE; CALCIUM DERIVATIVE; CITRATE CALCIUM; CITRATE SODIUM; DOXERCALCIFEROL; LANTHANUM CARBONATE; MAGNESIUM CARBONATE; MAGNESIUM HYDROXIDE; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER; STEROL DERIVATIVE; VITAMIN D DERIVATIVE; CHELATING AGENT; PHOSPHATE;

ARTICLE; BIOACCUMULATION; BLOOD VESSEL CALCIFICATION; BONE; BONE DEFECT; CENTRAL NERVOUS SYSTEM; CHRONIC DRUG ADMINISTRATION; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONSTIPATION; DIALYSIS; DIARRHEA; DIET RESTRICTION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG WITHDRAWAL; FECES IMPACTION; GASTROINTESTINAL SYMPTOM; HEMATOPOIETIC CELL; HUMAN; HYPERCALCEMIA; HYPERMAGNESEMIA; HYPERPHOSPHATEMIA; INFLAMMATION; LIPID METABOLISM; NAUSEA; NONHUMAN; OSTEOMALACIA; PHOSPHATE BLOOD LEVEL; PRESCRIPTION; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; SINGLE DRUG DOSE; SOFT TISSUE CALCIFICATION; TASTE DISORDER; VOMITING; BLOOD; DISORDERS OF MINERAL, ELECTROLYTE AND METAL METABOLISM; REVIEW;

CHELATING AGENTS; HUMANS; KIDNEY FAILURE, CHRONIC; PHOSPHATES; PHOSPHORUS METABOLISM DISORDERS;

EID: 33751564527     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001997     Document Type: Article

References (51)

1. Bleyer AJ. Phosphate binder usage in kidney failure patients. Expert Opin Pharmacother 2003; 4: 941-947.
2. Emmett M. A comparison of clinically useful phosphorus binders for patients with chronic kidney failure. Kidney Int 2004; 66(Suppl 90): S25-S32.
3. Pierratos A. Nocturnal home haemodialysis: an update on a 5-year experience. Nephrol Dial Transplant 1999; 14: 2835-2840.
4. Toussaint N, Boddington J, Simmonds R et al. Calcium phosphate metabolism and bone mineral density with nocturnal hemodialysis. Hemodial Int 2006; 10: 280-286.
5. Molony DA, Murthy B. Accumulation of metals and minerals from phosphate binders. Blood Purif 2005; 23(Suppl 1): 2-11.
6. Cannata-Andía JB, Fernández-Martin JL. The clinical impact of aluminium overload in renal failure. Nephrol Dial Transplant 2002; 17(Suppl 2): 9-12.
7. Wilhelm M, Jäger DE, Ohnesorge FK. Aluminium toxicokinetics. Pharmacol Toxicol 1990; 66: 4-9.
8. Salusky IB, Foley J, Nelson P et al. Aluminum accumulation during treatment with aluminium hydroxide and dialysis in children and young adults with chronic renal disease. N Engl J Med 1991; 324: 527-531.
9. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(Suppl 3): S12-S28.
10. Molitoris BA, Froment DH, Mackenzie TA et al. Citrate: a major factor in the toxicity of orally administered aluminum compounds. Kidney Int 1989; 36: 949-953.
11. Coburn JW, Mischel MG, Goodman WG et al. Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. Am J Kidney Dis 1991; 17: 708-711.
12. Slatopolsky E, Weerts C, Lopez-Hilker S et al. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 1986; 315: 157-161.
13. Salusky IB, Coburn JW, Foley J et al. Effects of oral calcium carbonate on control of serum phosphorus and changes in plasma aluminum levels after discontinuation of aluminum-containing gels in children receiving dialysis. J Pediatr 1986; 108(Part 1): 767-770.
14. Coladonato JA. Control of hyperphosphatemia among patients with ESRD. J Am Soc Nephrol 2005; 16: S107-S114.
15. Sheikh MS, Maguire JA, Emmett M et al. Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical in vitro and in vivo study. J Clin Invest 1989; 83: 66-73.
16. Salusky IB, Goodman WG. Adynamic renal osteodystrophy: is there a problem? J Am Soc Nephrol 2001; 12: 1978-1985.
17. Kurz P, Monier-Faugere MC, Bognar B et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994; 46: 855-861.
18. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483.
19. Guérin AP, London GM, Marchais SJ et al. Arterial stiffening and vascular calcifications in end-stage renal disease.Nephrol Dial Transplant 2000; 15: 1014-1021.
20. Oh J, Wunsch R, Turzer M et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 2002; 106: 100-105.
21. London GM, Guérin AP, Marchais SJ et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740.
22. Sherrard DJ. Aluminum and renal osteodystrophy. Semin Nephrol 1986; 6(Suppl 1): 5-11.
23. Salusky IB, Coburn JW, Brill J et al. Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. Kidney Int 1988; 33: 975-982.
24. Moriniere P, Cohen-Solal M, Belbrik S et al. Disappearance of aluminic bone disease in a long term asymptomatic dialysis population restricting A1(OH)3 intake: emergence of an idiopathic adynamic bone disease not related to aluminum. Nephron 1989; 53: 93-101.
25. Malluche HH, Monier-Faugere MC. Risk of adynamic bone disease in dialyzed patients. Kidney Int 1992; 38(Suppl): S62-S67.
26. Sherrard DJ, Hercz G, Pei Y et al. The spectrum of bone disease in end-stage renal failure - an evolving disorder. Kidney Int 1993; 43: 436-442.
27. Malluche HH, Faugere M-C, Wang G et al. No evidence of osteomalacia in dialysis patients treated with lanthanum carbonate up to 5 years. J Am Soc Nephrol 2004; 15: 270A (Abstract F-PO944).
28. London GM, Marty C, Marchais SJ et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004; 15: 1943-1951.
29. Guillot AP, Hood VL, Runge CF et al. The use of magnesium-containing phosphate binders in patients with end-stage renal disease on maintenance hemodialysis. Nephron 1982; 30: 114-117.
30. Morinière P, Vinatier I, Westeel PF et al. Magnesium hydroxide as a complementary aluminium-free phosphate binder to moderate doses of oral calcium in uraemic patients on chronic haemodialysis: lack of deleterious effect on bone mineralisation. Nephrol Dial Transplant 1988; 3: 651-656.
31. Delmez JA, Kelber J, Norwood KY et al. Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study. Kidney Int 1996; 49: 163-167.
32. Chertow GM, Burke SK, Raggi P, Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252.
33. Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815-1824.
34. Bleyer AJ, Burke SK, Dillon M et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kid Dis 1999; 33: 694-701.
35. Chertow GM, Burke SK, Dillon MA et al. Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999; 14: 2907-2914.
36. Burke SK, Dillon MA, Hemken DE et al. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients. Adv Ren Replace Ther 2003; 10: 133-145.
37. Qunibi WY, Hootkins RE, McDowell LL et al. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE study). Kidney Int 2004; 65: 1914-1926.
38. Salusky IB, Goodman WG, Sahney S et al. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. J Am Soc Nephrol 2005; 16: 2501-2508.
39. Raggi P, James G, Burke SK et al. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. J Bone Miner Res 2005; 20: 764-772.
40. Nikolov IG, Joki N, Maizel J et al. Pleiotropic effects of the non-calcium phosphate binder sevelamer. Kidney Int 2006; 70(suppl): S5-S12.
41. Ferramosca E, Burke S, Chasan-Taber S et al. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 2005; 149: 820-825.
42. Wilkes BM, Reiner D, Kern M et al. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients. Clin Nephrol 1998; 50: 381-386.
43. Yamada K, Fujimoto S, Tokura T et al. Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients. Ren Fail 2005; 27: 361-365.
44. D'Haese PC, Spasovski GB, Sikole A et al. A multicenter study on the effects of lanthanum carbonate (FosrenolTM) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 2003; 63(Suppl 85): S73-S78.
45. Hutchison AJ, Maes B, Vanwalleghem J et al. Efficacy, tolerability and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract 2005; 100: 8-19.
46. Joy MS, Finn WF on behalf of the LAM-302 Study Group. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 2003; 42: 96-107.
47. Finn WF, Hladik J, and the Lanthanum Study Group. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol 2004; 62: 193-201.
48. Berlove DJ, Martin H, Eworonsky P et al. Lanthanum accumulation in rats with adenine-induced chronic renal failure. J Am Soc Nephrol 2004; 15: 272A.
49. Lacour B, Lucas A, Auchère D et al. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int 2005; 67: 1062-1069.
50. Slatopolsky E, Liapis H, Finch J. Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int 2005; 68: 2809-2813.
51. Spasovski GB, Sikole A, Gelev S et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant. 2006; 21: 2217-2224.